NeuroOne reports fiscal Q4 2022 net loss of $1.4M; collaboration revenue jumps to $1.94M

NEUROONE MEDICAL TECHNOLOGIES Corp

Product revenue $69K in Q4 vs $48K prior year; full year $171K vs $178K.
Collaboration revenue $1.94M in Q4 from Zimmer Development Agreement, up from $5K.
Net loss $1.4M in Q4 vs $2.6M prior year; full year net loss $10.0M vs $9.9M.
Cash and short-term investments $11.1M at Sept. 30, 2022, up from $6.9M; no debt outstanding.
Operating expenses $3.3M in Q4 vs $2.6M; R&D $1.4M, SG&A $1.9M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal year ended September 30, 2022 results: net income $10.0 million.

Period: fiscal year ended September 30, 2022
Net income: $10.0 million
Result: reported results

Exact text from the filing

Net loss was $10.0 million for the full year fiscal 2022, compared to a net loss of $9.9 million in fiscal 2021.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal fourth quarter ended September 30, 2022 results: net income $1.4 million.

Period: fiscal fourth quarter ended September 30, 2022
Net income: $1.4 million
Result: reported results

Exact text from the filing

Net loss was $1.4 million for the fourth quarter of fiscal 2022, compared to a net loss of $2.6 million in the prior year period.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NEUROONE MEDICAL TECHNOLOGIES Corp filing history →

Source: SEC EDGAR

accession 0001213900-22-081976

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.